Article
09 February 2026 - by Michelle (Klein) Robb, Jennifer Carioto
What should life sciences companies know about risk adjustment for the Medicare, Medicaid, and ACA markets?
Article
10 October 2025 - by Jennifer Carioto, Sara Yi
We discuss key insights from the 2026 Medicare Advantage bids that life sciences leaders should consider when planning for the future.
Article
12 September 2025 - by Jennifer Carioto, Tracy Margiott
We examine five important ways actuaries can support and add value to the success of life sciences companies.
Article
08 November 2024 - by Jennifer Carioto, Melissa A. Caplen, Hanaa Siddiqi, Ben Diner
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Feller, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost.
Article
21 December 2023 - by Bruce S. Pyenson, Jennifer Carioto, Michael Rothschild, John Miller, Stephanie Leary
We discuss how the Inflation Reduction Act could affect Medicare Part D plans, members, the government, and pharmaceutical manufacturers.
Article
21 December 2023 - by Jennifer Carioto, Gabriela Dieguez, Tushar Makhija
We expect the financial implications of the Inflation Reduction Act to lead to a reassessment of formulary strategies by Medicare Part D plans.
Video
11 October 2023 - by Greg Sgrosso, Jennifer Carioto, Luis Maldonado, Todd Wanta
Employer Group Waiver Plans (EGWPs) have consistently provided millions of retirees stable medical and prescription drug coverage, but upcoming changes threaten that stability.
Article
29 September 2023 - by Jennifer Carioto, Tushar Makhija, Maggie Alston
We offer a primer on the Medicare Part D prescription drug rebates, with insights into the possible impact of the Inflation Reduction Act.
Article
15 February 2022 - by Gabriela Dieguez, Jennifer Carioto
Quantifying the impact of expanding biomarker testing coverage in the commercial and Medicaid markets.